Showing results (1-10 of 723) with videos related to

Sort By:
Pageof 73
Cancer Research and Treatment|July 27, 2019
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II StudiesMyung-Ju Ahn, Ji-Youn Han, Dong-Wan Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|December 11, 2025
MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancerByoung Chul Cho, Chaiyut Charoentum, Dong-Wan Kim, et al.
Cancer Cell|February 13, 2024
Re-inventing a better wheel? Serplulimab for squamous cell lung cancerDerek De-Rui Huang, James Chih-Hsin Yang
Yonsei Medical Journal|August 29, 2022
Lazertinib: on the Way to Its ThroneJiyun Lee, Min Hee Hong, Byoung Chul Cho
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 30, 2026
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief ReportHidetoshi Hayashi, Byoung Chul Cho, David R Spigel, et al.
Anticancer Research|March 31, 2021
CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung CancerSebastian Griesing, Bin-Chi Liao, James Chih-Hsin Yang
Therapeutic Advances in Medical Oncology|December 6, 2019
Second-line treatment of EGFR T790M-negative non-small cell lung cancer patientsBin-Chi Liao, Sebastian Griesing, James Chih-Hsin Yang
Pageof 73